The evaluation of Serum angiotensin-converting enzyme 2 (ACE2) levels and its relationship with clinical outcome in patients with Coronavirus disease 2019 (COVID-19)
S. Hashemi-Bajgani (Kerman, Islamic Republic of Iran), M. Samareh Fekri (Kerman, Islamic Republic of Iran), M. Hosseinib (Kerman, Islamic Republic of Iran), A. Baniasad (Kerman, Islamic Republic of Iran), A. Behzadi (Kerman, Islamic Republic of Iran), S. Movahedinia (Kerman, Islamic Republic of Iran)
Source: International Congress 2022 – Biomarkers in COVID-19
Session: Biomarkers in COVID-19
Session type: Thematic Poster
Number: 859
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Hashemi-Bajgani (Kerman, Islamic Republic of Iran), M. Samareh Fekri (Kerman, Islamic Republic of Iran), M. Hosseinib (Kerman, Islamic Republic of Iran), A. Baniasad (Kerman, Islamic Republic of Iran), A. Behzadi (Kerman, Islamic Republic of Iran), S. Movahedinia (Kerman, Islamic Republic of Iran). The evaluation of Serum angiotensin-converting enzyme 2 (ACE2) levels and its relationship with clinical outcome in patients with Coronavirus disease 2019 (COVID-19). 859
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|